Hanmi Pharm. Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,873 million compared to KRW 707.38 million a year ago. Net income was KRW 25,374.29 million compared to KRW 23,401.53 million a year ago. Basic earnings per share from continuing operations was KRW 2,037.2549 compared to KRW 1,876.4706 a year ago. Basic earnings per share was KRW 2,037.2549 compared to KRW 1,876.4706 a year ago.
For the nine months, sales was KRW 3,710.73 million compared to KRW 1,206.27 million a year ago. Net income was KRW 63,311.68 million compared to KRW 49,557.29 million a year ago. Basic earnings per share from continuing operations was KRW 5,083.3333 compared to KRW 3,974.5098 a year ago. Basic earnings per share was KRW 5,083.3333 compared to KRW 3,974.5098 a year ago.